Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 3/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | DPP4 | P27487 | 2/20 | 0.39 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.39 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.39 |
| ▸ | MBOAT4 | Q96T53 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 2/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.37 |
| ▸ | IDO1 | P14902 | 1/20 | 0.37 |
| ▸ | COPS5 | Q92905 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21526074 | 0.89 | SMN1; SMN2 (0.46) | HTTSMN1; SMN2DPP4DPP8P2RX7 | |
| SCHEMBL20356667 | 0.88 | SMN1; SMN2 (0.54) | HTTSMN1; SMN2DPP4DPP8P2RX7 | |
| SCHEMBL20356760 | 0.87 | GAA (0.38) | HTTSMN1; SMN2DPP4DPP8P2RX7 | |
| SCHEMBL21526053 | 0.84 | SMN1; SMN2 (0.50) | HTTSMN1; SMN2DPP4DPP8P2RX7 | |
| SCHEMBL20356578 | 0.83 | SMN1; SMN2 (0.44) | HTTSMN1; SMN2DPP4DPP8P2RX7 | |
| SCHEMBL21548933 | 0.82 | SMN1; SMN2 (0.61) | HTTSMN1; SMN2DPP4DPP8P2RX7 | |
| SCHEMBL21526073 | 0.81 | SMN1; SMN2 (0.44) | HTTSMN1; SMN2DPP4DPP8P2RX7 | |
| SCHEMBL20356750 | 0.81 | SMN1; SMN2 (0.44) | HTTSMN1; SMN2DPP4DPP8P2RX7 | |
| SCHEMBL21526039 | 0.80 | HTT (0.46) | HTTSMN1; SMN2DPP4DPP8P2RX7 | |
| SCHEMBL21548948 | 0.80 | PKM (0.36) | HTTSMN1; SMN2KMT2AHPGDKDM4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3564216-B1 | PYRIMIDINE DERIVATIVE | DAIICHI SANKYO CO LTD (JP) | 2021-10-27 | — | — | EP | disclosed |
| EP-3564216-B1 | PYRIMIDINE DERIVATIVE | DAIICHI SANKYO CO LTD (JP) | 2021-10-27 | — | — | EP | disclosed |
| US-11034659-B2 | Pyrimidine derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2021-06-15 | — | — | US | disclosed |
| US-11034659-B2 | Pyrimidine derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2021-06-15 | — | — | US | disclosed |
| US-20200172494-A1 | PYRIMIDINE DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2020-06-04 | — | — | US | disclosed |
| US-20200172494-A1 | PYRIMIDINE DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2020-06-04 | — | — | US | disclosed |
| EP-3564216-A1 | PYRIMIDINE DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2019-11-06 | — | — | EP | disclosed |
| EP-3564216-A1 | PYRIMIDINE DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2019-11-06 | — | — | EP | disclosed |
| CN-110198930-A | Pyrimidine derivatives | 第一三共株式会社 | 2019-09-03 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11034659-B2 | Pyrimidine derivative | GPR39, CFTR, TMEM109 | HTT 3973/4885SMN1; SMN2 2983/4885DPP4 4340/4885 |
| US-20200172494-A1 | PYRIMIDINE DERIVATIVE | GPR39, CFTR, TMEM109 | HTT 3973/4885SMN1; SMN2 2983/4885DPP4 4340/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.